【摘要】 目的探讨乳腺癌患者血清巨噬细胞移动抑制因子(MIF)水平与其临床特征的关系。方法收集2006年10月至2007年3月乳腺癌患者54例和体检正常的女性健康对照46例血清,用酶联免疫吸附法检测血清MIF、白细胞介素8(IL-8)及血管内皮生长因子(VEGF)的浓度,分析其与临床特征的关系。结果乳腺癌组血清MIF、IL-8及VEGF浓度均明显高于健康对照组(P<0.05),MIF与肿瘤的分期和淋巴结转移相关(P<0.05),乳腺癌组患者血清MIF与IL-8相关(r=0.612,P<0.01)。结论 MIF可能参与了乳腺癌的疾病进展过程,可作为反应肿瘤侵袭的一个有用的生物标记物。更多还原

【Abstract】 Objective To study the relationship between serum macrophage migration inhibitory factor(MIF) levels and clinical features in the patients with breast cancer.Methods Enzyme-linked immunosorbent assay was used to detect the concentration of MIF,IL-8 and VEGF in sera of 54 patients with breast cancer and 46 healthy controls from October 2006 to March 2007.The relationship between serum MIF,IL-8 and VEGF levels and clinical features was analyzed.Results The levels of MIF,IL-8 and VEGF in the sera of patients with breast cancer were significantly increased compared to healthy controls(P<0.05).The levels of MIF in breast cancer were significantly correlated with clinical progression pathology stages(P<0.05) and lymph node metastasis(P<0.05).Serum MIF levels correlated positively with serum IL-8 levels(r=0.612,P<0.01).Conclusion MIF may be involved in the progression of breast cancer and serum MIF may be a useful biological marker of tumor invasiveness for patients with breast cancer.更多还原